Chargement des cours...
Prévisions
L'objectif de cours moyen des analystes est de 11,64 € (+335,96 %). La médiane est de 11,64 € (+335,96 %).
| Acheter |
16 |
| Conserver |
0 |
| Vendre |
0 |
Discussions dans la communauté
Il n'y a pas encore de discussion sur cet actif.
Lancer une discussionActualités Accéder au fil d'actualités
Ardelyx aims for profitability in 2027 despite payers' cost pressure
At the Cantor Global Healthcare Conference, Ardelyx confirmed it remains on track to become profitable in 2027, supported by stronger product margins and revenue growth. IBSRELA generated $274 million in revenues in 2024 and is expected to reach $350–370 million in 2025, while XPHOZAH is forecast to remain at $110–120 million for 2025 and paid prescriptions recently rose by 25%. Payers have introduced step-therapy mandates and stricter authorization rules, prompting Ardelyx to increase its reimbursement team and launch digital direct-to-consumer advertising. The company has $282 million in cash, emphasizes patent protection for IBSRELA through 2042, and expects Phase III results for a CIC study in 2026. » Plus sur de.investing.com
Ardelyx stock plunges 18%; put trading explodes
Ardelyx stock fell 18.4% on Friday to $3.98. Options activity rose to 11,147 contracts, of which 10,676 were puts; 10,004 contracts were for a put expiring October 16, 2026 with a $4 strike. The 3‑month volatility climbed to 74.93% and the 3‑month skew increased markedly, suggesting heightened hedging or speculative short bets. » Plus sur de.investing.com
Ardelyx cuts outlook for IBSRELA and withdraws XPHOZAH target, stock plunges after Q2 results
Ardelyx reported record product revenue in Q2 of $118 million (+31% year-on-year), but management lowered the full-year forecast for IBSRELA to $350–370 million and withdrew the previous sales target for XPHOZAH. The company cited tightened payer access restrictions and uncertainty after the end of TDAPA, which is slowing the growth of new patients. The stock fell about 18% in after-hours trading to $3.99 despite improved loss figures and a continued expectation of profitability in 2027. » Plus sur de.investing.com
Ardelyx sees strong Q1 growth and sets $1bn IBSRELA target for 2029
Ardelyx reported Q1 FY2026 total product revenue up 38% year-over-year, driven by a 58% rise in IBSRELA sales and strong XPHOZAH performance. Ladenburg initiated coverage with a Buy and $16 price target, citing expansion of IBSRELA demand, pipeline growth and financial flexibility for further investment. Management aims for at least $1 billion in annual IBSRELA revenue by 2029 while pursuing external opportunities aligned with its capital allocation strategy. » Plus sur finance.yahoo.com
Ardelyx shareholders elect directors and approve amendment to equity-incentive plan
At the annual meeting shareholders confirmed three directors (Robert Bazemore, Muna Bhanji, R.Ph, Richard Rodgers) through 2029 and approved the second amendment to the Amended and Restated 2014 Equity Incentive Award Plan. The non-binding say-on-pay vote was approved and the frequency of compensation votes was set to annual. Ernst & Young was ratified as auditor for fiscal 2026. Ardelyx reported a net loss of $37.6 million (‑$0.15 per share) for Q1/2026, missing both EPS and revenue forecasts but cited strong year-over-year growth; the company also presented long-term safety data for XPHOZAH showing no clinically meaningful electrolyte changes. » Plus sur de.investing.com
Données financières de l'entreprise
| (EUR) | septembre 2026 | YoY |
|---|---|---|
| Chiffre d'affaires | 112,7 M | 19,88 % |
| Bénéfice brut | 108,69 M | 20,97 % |
| Bénéfice net | -650,66 k | 21,20 % |
| EBITDA | 3,55 M | 48,04 % |
Données fondamentales
| Indicateur | Valeur |
|---|---|
Capitalisation boursière | 653,9 M € |
Nombre d'actions | 249,19 M |
Plus haut/bas sur 52 semaines | 7,52 € - 2,51 € |
| Dividendes | Non |
Bêta | 0,68 |
Ratio P/E | -13,05 |
Ratio PEG | -7,29 |
Ratio P/B | 4,47 |
Ratio P/S | 1,56 |
Profil de l'entreprise
Ardelyx, Inc., une société biopharmaceutique, découvre, développe et commercialise des médicaments destinés au traitement des domaines thérapeutiques gastro-intestinal et cardiorénal aux États-Unis et à l'international. Le produit candidat principal de la société est le tenapanor, qui a achevé un essai clinique de phase III pour le traitement des patients atteints du syndrome du côlon irritable avec constipation, ainsi qu'un essai clinique de phase III visant à contrôler le taux sérique de phosphore chez les patients adultes atteints d'insuffisance rénale chronique (IRC) sous dialyse, ou hyperphosphatémie. La société développe également le RDX013, un sécrétagogue du potassium, destiné au traitement de l'hyperkaliémie, soit un taux sérique de potassium élevé, un problème touchant certains patients atteints de maladies rénales et/ou cardiaques ; ainsi que le RDX020, un programme en phase précoce dans l'acidose métabolique, un grave trouble électrolytique chez les patients atteints d'IRC. La société a conclu des accords avec Kyowa Kirin au Japon, Fosun Pharmaceutical Industrial Development Co. Ltd. en Chine et Knight Therapeutics, Inc. au Canada pour le développement et la commercialisation du tenapanor dans leurs territoires respectifs. La société était auparavant connue sous le nom de Nteryx, Inc. et a changé son nom en Ardelyx, Inc. en juin 2008. Ardelyx, Inc. a été constituée en 2007 et son siège social se trouve à Waltham, Massachusetts.
| Nom | Ardelyx |
| PDG | Michael G. Raab |
| Siège social | Waltham,
ma États-Unis |
| Site web | |
| Secteur | Santé |
| Industrie | Biotechnologie |
| Introduction en bourse | 19/06/2014 |
| Employés | 489 |
Symboles boursiers
| Bourse | Symbole |
|---|---|
NASDAQ | ARDX |
Frankfurt | 41X.F |
Düsseldorf | 41X.DU |
SIX | 41X.SW |
München | 41X.MU |
